Antiviral 1 Flashcards
Nucleoside analogues
Acyclovir Famciclovir Valacyclovir Panciclovir Ganciclovir Valganciclovir Cidofovir Trifluridine
Nucleoside analogues - MoA
Prodrugs that are converted to monophosphate by virus enzymes, and then to active triphosphate metabolites by host enzymes. Competitive inhibition of viral DNA polymerase.
Acyclovir - Clinical use
HSV, VZV Prophylaxis of CMV Chickenpox IV form: most effective treatment for serious herpesvirus infections, including herpetic encephalitis and severe HSV and VZV infections in immunocompromised patients Topical form: herpes genitalis and mild mucocutaneous infections in immunocompromised patients. In cases of herpes genitalis, however, topical form is less effective than oral form
Herpetic encephalitis
Acyclovir - Adverse effects
Well tolerated Headache, GI disturbances, rash (General for all the nucleoside analoges) IV: phlebitis + reversible renal dysfunction
Famciclovir - Clinical use
HSV VZV
Valacyclovir - Clinical use
HSV, VZV Prophylaxis of CMV , such as in bone marrow and organ transplant recipients and in persons with HIV
Panciclovir - Clinical use
Herpes labialis
Ganciclovir - Clincal use
Prevent CMV diseases, including retinitis, esophagitis, and colitis HSV: keratitis (infection of the corneal epithelium) caused by HSV-1 and HSV-2
Ganciclovir - Adverse effects
Leukopeina, thrombocytopenia Retinal detachment, liver and renal dysfunction
Ganciclovir - Interactions
Severe myelosupression with zidovudine
Valganciclovir - Clinical use
Prevent and treatment of less severe CMV infections, including those occurring in renal and heart transplant patients
Cidofovir - Clinical use
Prevent CMV diseases resistant to ganciclovir
Cidofovir - Contraindications
Contraindicated in patients taking other nephrotoxic drugs, such as aminoglycosides and amphotericin B.
Cidofovir - Adverse effects
Nephrotoxicity, neutropenia, metabolic acidosis.
Trifluridine - Clinical use
Ocular herpervirus infections, primarily herpetic epithelial keratitis and keratoconjuctivitis
Pyrophosphate derivative (HSV drug)
Foscarnet
Foscarnet - MoA
Blocks pyrophosphate-binding sites on viral DNA polymerase and prevents attachment of nucleotide precursor to DNA. Does not need activation by viral/host kinases.
Foscarnet - Clinical use
CMV, VZV, HSV CMV retinitis in AIDS patients Acyclovir-resistant HSV infections Shingles Combined with ganciclovir to treat infections resistant to either drug alone because of their synergistic effect on viral DNA polymerase
Foscarnet - Adverse effects
Renal impairment and acute renal failure, hematologic deficiencies, cardiac arrhythmias + heart failure, seizures, pancreatitis Renal toxicity can be minimized by administering intravenous fluids to induce diuresis before and during treatment
Nucleoside reverse transcriptase inhibitors (NRTIs)
Didanosine Lamivudine Stavudine Emtricitabine Zidovudine (ZDV) Abacivir (ABC) Tenofovir